MTOR and cancer: Ku-0063794 and Ku-006865047,48, developed by KuDOS Pharmaceuticals (now part of AstraZeneca), are also examples of early ATP-competitive mTOR inhibitors which exhibit great anti-proliferative potential against cancer cellsin vitro.